Gilead Sciences and Unite for HER Launch Free Integrative Care Program for Metastatic Breast Cancer Patients

By Advos

TL;DR

Unite for HER and Gilead Sciences offer a competitive edge by providing free integrative care to underserved metastatic breast cancer patients, enhancing treatment adherence and quality of life.

The Metastatic Breast Cancer Sustainer Program methodically delivers free integrative therapies and support, including acupuncture and nutrition, to improve patient outcomes and treatment persistence.

This partnership humanistically addresses healthcare disparities, offering dignity and equity through free, comprehensive care to marginalized metastatic breast cancer patients, fostering a healthier, more inclusive society.

Discover how Unite for HER and Gilead Sciences' innovative program transforms lives with free integrative therapies for metastatic breast cancer patients, a beacon of hope and support.

Found this article helpful?

Share it with your network and spread the knowledge!

Gilead Sciences and Unite for HER Launch Free Integrative Care Program for Metastatic Breast Cancer Patients

Gilead Sciences, Inc. has partnered with Unite for HER (UFH) to introduce the 'Metastatic Breast Cancer Sustainer Program,' a groundbreaking initiative aimed at providing free integrative care to Black, Hispanic, and underserved metastatic breast cancer patients across the United States. This program offers a range of services including acupuncture, professional counseling, personalized nutrition support, and fitness memberships, all at no cost to the patient.

Sue Weldon, Founder and CEO of Unite for HER, highlighted the program's impact, stating it has become a vital lifeline for members, particularly those from marginalized communities. The initiative not only supports patients in adhering to their treatment plans but also significantly improves their quality of life by addressing the whole person—mind, body, and spirit.

Carmen Villar, Senior Vice President of Global Giving, Advocacy, and Responsibility at Gilead Sciences, emphasized the company's commitment to innovative solutions that meet the unique needs of the metastatic breast cancer community. This partnership underscores Gilead's dedication to making a measurable difference in the lives of patients through equitable access to care.

Since its inception in October 2023, the program has already supported over 2,823 patients, with Gilead Sciences' funding enabling a focused effort to assist Black, Hispanic, and underserved populations. For more information on the program and its services, visit https://www.uniteforher.org.

Curated from 24-7 Press Release

blockchain registration record for this content
Advos

Advos

@advos